New hope for schizophrenia: experimental drug targets severe symptoms in hospitalized patients
NCT ID NCT06963034
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 26 times
Summary
This study tests whether the experimental drug NBI-1117568 can reduce schizophrenia symptoms like hallucinations and delusions better than a placebo. About 284 adults with schizophrenia who need hospital care will take the drug or a placebo for 5 weeks while staying in the hospital. The main goal is to see if symptoms improve more with the drug than with placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Neurocrine Clinical Site
RECRUITINGBryant, Arkansas, 72022, United States
-
Neurocrine Clinical Site
RECRUITINGLittle Rock, Arkansas, 72211, United States
-
Neurocrine Clinical Site
RECRUITINGAnaheim, California, 92805, United States
-
Neurocrine Clinical Site
RECRUITINGPico Rivera, California, 90660, United States
-
Neurocrine Clinical Site
RECRUITINGSan Diego, California, 92123, United States
-
Neurocrine Clinical Site
RECRUITINGSherman Oaks, California, 91403, United States
-
Neurocrine Clinical Site
RECRUITINGTorrance, California, 90504, United States
-
Neurocrine Clinical Site
RECRUITINGHollywood, Florida, 33024, United States
-
Neurocrine Clinical Site
RECRUITINGMiami Lakes, Florida, 33016, United States
-
Neurocrine Clinical Site
RECRUITINGAtlanta, Georgia, 30331, United States
-
Neurocrine Clinical Site
RECRUITINGDecatur, Georgia, 30030, United States
-
Neurocrine Clinical Site
RECRUITINGSnellville, Georgia, 30078, United States
-
Neurocrine Clinical Site
RECRUITINGChicago, Illinois, 60640, United States
-
Neurocrine Clinical Site
RECRUITINGGaithersburg, Maryland, 20877, United States
-
Neurocrine Clinical Site
RECRUITINGWatertown, Massachusetts, 02472, United States
-
Neurocrine Clinical Site
RECRUITINGMarlton, New Jersey, 08053, United States
-
Neurocrine Clinical Site
RECRUITINGStaten Island, New York, 10314, United States
-
Neurocrine Clinical Site
RECRUITINGThe Bronx, New York, 10461, United States
-
Neurocrine Clinical Site
RECRUITINGAustin, Texas, 78754, United States
-
Neurocrine Clinical Site
RECRUITINGDeSoto, Texas, 75115, United States
-
Neurocrine Clinical Site
RECRUITINGHouston, Texas, 77043, United States
Conditions
Explore the condition pages connected to this study.